Sinchareonkul v. Fahnemann

Court of Chancery of Delaware·Decided January 22, 2015·No. CA 10543-VCL·Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

VEERASITH SINCHAREONKUL, )

)

Plaintiff, )

)

v. ) C.A. No. 10543-VCL )

THOMAS FAHNEMANN, RICHARD ) EHRENFELDNER, GERHARD ) KLINGENBRUNNER, and CLEMENS ) EICHLER, )

)

Defendants. )

MEMORANDUM OPINION

Submitted: January 20, 2015 Decided: January 22, 2015

A. Thompson Bayliss, Steven C. Hough, ABRAMS & BAYLISS LLP, Wilmington, Delaware; Attorneys for Plaintiff.

Samuel A. Nolen, Kevin M. Gallagher, Matthew D. Perri, RICHARDS, LAYTON & FINGER, P.A., Wilmington, Delaware; Attorneys for Defendants.

LASTER, Vice Chancellor.

The plaintiff is a director of non-party Sempermed USA, Inc. (“SUSA” or the “Company”), a Delaware corporation. He seeks declaratory judgments invalidating two bylaws that confer disproportionate voting power on the defendants, who are also directors of the Company. He seeks a third declaratory judgment invalidating a resolution adopted by the defendants through the exercise of their disproportionate voting powers. He has moved to schedule an expedited hearing on an application for a preliminary injunction, which he asks to be heard before February 10, 2015. Although the plaintiff has stated a colorable claim, he has not identified a sufficient threat of irreparable harm to warrant an immediate injunction hearing. Instead, good cause exists for a two-day trial in approximately 90-120 days so that a final decree can be entered.

I. FACTUAL BACKGROUND The operative facts are drawn from the complaint and the documents it incorporates by reference. “In assessing a motion to expedite, the Court need not—and, indeed, should not—make factual findings. It is, instead, guided by the well-pled, verified allegations of the Complaint.” Shocking Techs., Inc. v. Michael, 2012 WL 165561, at *1 (Del. Ch. Jan. 10, 2012). At this procedural stage, the plaintiff receives the benefit of all reasonably conceivable inferences.1 Certain seemingly non-controversial background facts have been drawn from a declaration provided by defendant Clemens Eichler.

1 “[T]he standard for expedition, colorability, which simply implies a non-frivolous set of issues, is even lower that the „conceivability‟ standard applied on a motion to dismiss.” In re BioClinica, Inc. S’holder Litig., 2013 WL 5631233, at *1 n.1 (Del. Ch. Oct. 16, 2013). “In considering a motion to dismiss . . . the Court takes the well-pleaded allegations of the complaint as true and affords the plaintiff the benefit of all reasonable inferences that can be drawn from

A. The Company Semperit Technische Produkte Gesellschaft m. b. H. (“Semperit”), Sri Trang Agro-Industry Public Co., Ltd. (“Sri Trang”), and Siam Sempermed Corporation Ltd. (“Siam Sempermed”) agreed to form the Company in 1998 for the purposes of manufacturing latex surgical gloves and then distributing and selling them in the United States market. Each of the stockholders brought business expertise to the venture. Semperit is a world-wide manufacturer, producer, and distributor of specialized rubber- based products. Its medical products include a wide range of examination, protective, and surgical gloves, which it distributes under several brands, including the SEMPERMED trademark. Sri Trang has experience sourcing field latex and manufacturing latex concentrate and other rubber products. Siam Sempermed manufactures latex gloves.

To document their business relationship, Semperit, Sri Tang, and Siam Sempermed entered into a Joint Venture Agreement dated April 30, 1998 (the “JV Agreement” or “JVA”). The JV Agreement called for SUSA‟s formation as a Delaware corporation. It contemplated that SUSA would have an eight member board of directors (the “Board”), evenly split between nominees of Semperit and Sri Trang. JVA § 6.1. To avoid deadlock, it provided as follows:

The chairman of the board of directors shall be elected out of the four (4)

directors nominated by Semperit and shall have a casting vote. Therefore, if no majority can be obtained within the board of directors on any such issue

those allegations.” Shamrock Activist Value Fund, L.P. v. iPass Inc., 2006 WL 3824882, at *1 (Del. Ch. Dec. 15, 2006). A fortiori, at least the the same plaintiff-friendly standard, if not a somewhat more plaintiff-friendly standard, should apply to a motion to expedite.

or resolution, the chairman of the board of directors shall have a second vote. However, the chairman of the board of directors shall have no casting (tie breaking vote) vote in the matters described in Article 6.4 (7), (9) and

2

(18) hereof.

Embracing the language of the provision, this decision refers to the tiebreaking vote allocated to the chairman as the “Casting Vote.”

The JV Agreement acknowledged that the Company would have a certificate of incorporation and bylaws, but provided that “[i]n the event that any conflict or discrepancy arises between such Certificate of Incorporation and this Agreement, the provisions of the latter [i.e., the JV Agreement] shall prevail and the Certificate of Incorporation shall be promptly amended accordingly.” JVA § 3.2. The JV Agreement also provided for mandatory arbitration of any disputes between the parties:

Any dispute between the parties under and in connection with this Agreement shall be decided by three arbitrators appointed under the Rules of Conciliation and Arbitration of the International Chamber of Commerce in Paris. The place of Arbitration shall be Zürich, Switzerland, the language of the arbitration proceeding shall be English.

Documentary evidence may be submitted in a different language, unless the arbitration tribunal requests the submitting party to submit a translation thereof. The arbitral award shall determine the liability of the parties as to the costs of the arbitration, including reasonable attorneys, [sic] fees incurred by the parties. Judgment upon the award may be entered in any court having jurisdiction or application may be made to such court for a judicial acceptance of the award and for an order of enforcement, as the case may be.

2 JVA § 6.3 (footnote added). Sections (7), (9) and (18) of Article 6.4 are not applicable here. See id. § 6.4(7) (addressing the “entry into any new business requiring investment in excess of 20% of [the Company‟s] capital per project or the abandonment of an existing line of business”); § 6.4(9) (addressing the “mortgage or disposal of properties or assets of [the Company] exceeding per transaction 10% of [the Company‟s] capital”); § 6.4(18) (addressing “any modification of the Rules of management (Art. 7.3)”).

JVA § 20.2.

SUSA‟s certificate of incorporation (the “Charter”) and its bylaws implemented the JV Agreement‟s governance scheme imperfectly. Under the Charter, SUSA‟s authorized capitalization consists of 4,000 shares of common stock divided into three series: 2,000 shares of Series A common stock, 1,000 shares of Series B common stock, and 1,000 shares of Series C common stock. Siam Sempermed owns the Series A common stock, Sri Trang owns the Series B common stock, and Semperit owns the Series C common stock. As contemplated by the JV Agreement, the Charter fixes the number of directors at eight, with four elected by the holders of the Series B common stock and four elected by the holders of the Series C common stock. Charter Arts. FOURTH C.3 and SEVENTH. For simplicity, this decision refers to the directors elected by the holders of the Series B common stock as the “Sri Trang Directors” and the directors elected by the holders of the Series C common stock as the “Semperit Directors.”

The Charter does not provide for the chairman to be designated from among Semperit Directors, nor does it grant the chairman the Casting Vote. These provisions appear in the bylaws. Article III, § 11 of the bylaws states:

Free access — add to your briefcase to read the full text and ask questions with AI

Sinchareonkul v. Fahnemann, (Del. Ct. App. 2015).

Sinchareonkul v. Fahnemann (Sinchareonkul v. Fahnemann) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Crown Emak Partners, LLC v. Kurz
992 A.2d 377 (Supreme Court of Delaware, 2010)
Gatz v. Ponsoldt
925 A.2d 1265 (Supreme Court of Delaware, 2007)
Roven v. Cotter
547 A.2d 603 (Court of Chancery of Delaware, 1988)
McMullin v. Beran
765 A.2d 910 (Supreme Court of Delaware, 2000)
Waggoner v. Laster
581 A.2d 1127 (Supreme Court of Delaware, 1990)
Carmody v. Toll Bros., Inc.
723 A.2d 1180 (Court of Chancery of Delaware, 1998)
Staar Surgical Co. v. Waggoner
588 A.2d 1130 (Supreme Court of Delaware, 1991)
Centaur Partners, IV v. National Intergroup, Inc.
582 A.2d 923 (Supreme Court of Delaware, 1990)
Jones Apparel Group, Inc. v. Maxwell Shoe Co.
883 A.2d 837 (Court of Chancery of Delaware, 2004)
Reis v. Hazelett Strip-Casting Corp.
28 A.3d 442 (Court of Chancery of Delaware, 2011)
Gentile v. Rossette
906 A.2d 91 (Supreme Court of Delaware, 2006)
Box v. Box
697 A.2d 395 (Supreme Court of Delaware, 1997)
Sample v. Morgan
914 A.2d 647 (Court of Chancery of Delaware, 2007)
Airgas, Inc. v. Air Products & Chemicals, Inc.
8 A.3d 1182 (Supreme Court of Delaware, 2010)
C & J Energy Services, Inc. v. City of Miami General Employees'
107 A.3d 1049 (Supreme Court of Delaware, 2014)
Federal United Corp. v. Havender
11 A.2d 331 (Supreme Court of Delaware, 1940)
BVF Partners L.P. v. New Orleans Employees' Retirement System
59 A.3d 418 (Supreme Court of Delaware, 2012)
Carsanaro v. Bloodhound Technologies, Inc.
65 A.3d 618 (Court of Chancery of Delaware, 2013)
Boilermakers Local 154 Retirement Fund v. Chevron Corp.
73 A.3d 934 (Court of Chancery of Delaware, 2013)